RE: Mcw11 May 2025 18:55
Semantic
Not sure if you can answer this or not. If the survival rate is 34 months (from the last RNS update) and the trial only started 38 months ago does that mean the average (mean, I assume, not median) could actually increase for the phase 1 patients currently enrolled?
Or is that 34 months from initial reoccurrence of GBM rather than starting the trial?
What I am trying to ask in a roundabout way is could the 34 months actually have increased by the time phase 2 starts?
Thanks in advance